Fact checks · Repurposed drugs
“Can low-dose naltrexone improve my MS symptoms or stop the disease?”
The bottom line
Small trials give inconsistent signals for quality-of-life benefits, and low-dose naltrexone has not been shown to prevent MS relapses or disability progression.
Why people are talking about it
Low-dose naltrexone (LDN) developed a following through patient anecdotes and advocacy for repurposing an existing medicine. Claims about endorphins and immune regulation offer a plausible-sounding explanation, but a proposed mechanism is not proof of clinical benefit.
What the research says
Cree and colleagues' 2010 double-masked, placebo-controlled crossover pilot enrolled 80 people with MS, of whom 60 completed the trial. Eight weeks of 4.5 mg nightly naltrexone improved some self-reported mental-health, pain-impact and perceived-cognitive measures, but missing data and dropouts substantially reduced statistical power. Sharafaddinzadeh and colleagues' 2010 randomized, double-blind, placebo-controlled trial enrolled 96 people with relapsing-remitting or secondary progressive MS over 17 weeks. It found no meaningful between-group differences across most quality-of-life measures, including pain, energy and emotional well-being. These small, short studies do not establish a consistent symptomatic benefit and were not evidence that LDN prevents relapses, new MRI lesions or disability progression.
What we don't know yet
It remains unclear whether particular symptoms or patient groups benefit enough to justify treatment. Larger, longer controlled trials would be needed to establish durable benefit and better characterize safety alongside contemporary MS therapies.
Risks and costs
Short trials generally found LDN well tolerated, but vivid dreams have been reported and small studies cannot exclude uncommon or long-term harms. Naltrexone blocks opioid effects, so opioid pain medicines and any history of opioid dependence need explicit prescriber review. Off-label prescribing and preparation can involve private prescription or compounding costs, and liver disease also needs discussion. LDN should not replace a proven DMT or prompt an unsupervised treatment interruption.
Questions to bring to your neurologist
- Which specific symptom would we target, and how would we decide whether LDN is helping?
- Do any of my medicines, especially opioid painkillers, or liver problems make naltrexone unsuitable?
- What better-supported symptom treatments should I consider while continuing appropriate disease-modifying treatment?
Sources
This is information, not medical advice. Talk to your neurologist before changing anything.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error